13,14-二氢前列腺素f2alpha | 27376-74-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 13,14-二氢前列腺素f2alpha
• 英文名称: 13,14-dihydro-PGF_2α
• 英文别名: 13,14-Dihydrodinoprost；13,14-Dihydroprostaglandin F2alpha；(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoctyl]cyclopentyl]hept-5-enoic acid
• CAS: 27376-74-5
• 化学式: C₂₀H₃₆O₅
• 分子量: 356.503
• InChiKey: LLQBSJQTCKVWTD-NFUXFLSFSA-N

物化性质

• 溶解度：
  10 mM Na2CO3：>6.5 mg/ml（来自 PGF2a）； DMF：>100 mg/ml（来自 PGF2a）； DMSO：>100 mg/ml（来自 PGF2a）；乙醇：>100 mg/ml（来自 PGF2a）； PBS pH 7.2：>10 mg/ml（来自 PGF2a）

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (Z)-7-{(1R,2R,3R,5S)-5-Hydroxy-3-(tetrahydro-pyran-2-yloxy)-2-[(S)-3-(tetrahydro-pyran-2-yloxy)-octyl]-cyclopentyl}-hept-5-enoic acid 在 溶剂黄146 作用下， 生成 13,14-二氢前列腺素f2alpha
  参考文献：
  名称：

  DE2347630

  摘要：

  公开号：

文献信息

• Compounds And Compositions for the Treatment of Ocular Disorders
  申请人：Graybug Vision, Inc.

  公开号：US20170080092A1

  公开（公告）日：2017-03-23

  The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

  该披露描述了前药和前列腺素的衍生物、碳酸酐酶抑制剂、激酶抑制剂、β-肾上腺素受体拮抗剂和其他药物，以及含有这些前药和衍生物的受控释放配方，用于治疗眼部疾病。
• 13,14-Dihydro-PGF2BETA and its isopropyl ester
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0628545A1

  公开（公告）日：1994-12-14

  13,14-dihydro-prostaglandin F2β and its isopropyl ester of the formula: reduce intraocular pressure at low concentration and have low stimulus and are therefore useful for preventing and/or treating glaucoma.

  13,14-二氢-前列腺素F2β及其异丙酯酯化物：在低浓度下可降低眼内压力，并具有低刺激性，因此可用于预防和/或治疗青光眼。
• PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES
  申请人：MARTYNOW Jacek

  公开号：US20080207926A1

  公开（公告）日：2008-08-28

  The invention relates to a process for the preparation of 13,14-dihydro-PGF 2α derivatives of R or S configuration at carbon 15, represented by the general formula (I), wherein the identity of the substituents is defined in the description. Compounds of the formula (I) are valuable biologically-active substances or intermediates in the preparation thereof. The invention especially relates to the process for preparation of 13,14-dihydro-15(R)-17-substituted-18,19,20-trinor-PGF 2α , i.e., latanoprost.

  本发明涉及一种制备在碳15处具有R或S构型的13,14-二氢-PGF2α衍生物的方法，该衍生物由通式（I）表示，其中置换基的身份在说明中定义。式（I）化合物是有价值的生物活性物质或制备中间体。本发明特别涉及制备13,14-二氢-15（R）-17-取代-18,19,20-三去甲-PGF2α，即拉坦前列素的方法。
• METHOD FOR SCREENING OF PROSTAGLANDIN COMPOUNDS COMPRISING AN OPTIMAL FORMULATION FOR THE ENHANCEMENT OF HAIR GROWTH AND THE STIMULATION OF FOLLICULAR ANAGEN AND FORMULATIONS RESULTING THEREFROM
  申请人：Maxey Kirk M.

  公开号：US20090088473A1

  公开（公告）日：2009-04-02

  A method for developing Prostaglandin F 2α analogs for enhancing and sustaining the growth of eye lashes. The exemplary method first provides a method for determining the ability of a FP receptor agonist test compound having unknown hair growth ability to induce hair growth in its free acid form. The test compound may then be provided in its amide, or slowly hydrolyzing form and ester form, or rapidly hydrolyzing form to determine the relative hydrolysis rate within corneal tissue. Depending upon its hair growth ability and relative hydrolysis rates, the Prostaglandin F 2α analog in one or more forms may be used an ingredient in a binary cosmetic prodrug designed for enhancing and sustaining the growth of eye lashes.
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Graybug Vision, Inc.

  公开号：US20180028673A1

  公开（公告）日：2018-02-01

  The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.